Abbott (ABT) announced it has completed the acquisition of Exact Sciences (EXAS), establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. Pursuant to the terms of the merger agreement, upon completion of the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition, March 20, 2026, was the last day of trading of Exact Sciences shares on the Nasdaq Stock Market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- SCHD ETF Slips Ahead of Portfolio Reshuffle — UNH, QCOM In; HAL, VLO Out
- Abbott expects Exact Sciences acquisition to close on March 23
- Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates
- 3 ‘Strong Buy’ Stocks Analysts Recommend as Stagflation Fears Emerge
- Private Markets: Mind Robotics, Nexthop AI land $500M rounds